arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Caribou Biosciences, Inc.

CRBU

$0.41 ▼ -0.03 (-7.02%) at close

8 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Caribou Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $38.3M

Dividend Yield —

Revenue Growth 11.7% ↗

Op. Margin None

ROIC -121.0% ↘

FCF / Share $-1.20 ↗

Trailing P/E —

Price / Book 0.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$11.16M

↑ +11.7% —

Net Income Profit after all expenses

$-148.12M

↑ +0.7% —

Operating Margin Operating profit as % of sales

-336.6%

↓ -15.2% —

FCF / Share Free cash flow per share

$-1.20

↑ +24.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	11.7% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+46%)	-71.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-988%)	148.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1761%)	44.3% Excellent → Excellent Stable Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+454%)	-22.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-379%)	113.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1320%)	—	—
EPS Growth YoY (%)	3.6% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	-19.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	15.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	22.3% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	0.7% Caution ↑ Caution Improving Year-over-year change in net income	-46.1% Weak ↑ Weak Improving Year-over-year change in net income	-2.7% Weak ↑ Weak Improving Year-over-year change in net income	-48.6% Weak ↑ Weak Improving Year-over-year change in net income	-95.1% Weak Weak Year-over-year change in net income	-46.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	24.1% Good ↑ Good Improving Year-over-year change in free cash flow	-11.5% Weak ↑ Weak Improving Year-over-year change in free cash flow	11.3% Fair Fair Year-over-year change in free cash flow	-46.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	-7.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	1.4% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	40.8% Excellent Excellent Compound annual revenue growth over 3 years	33.8% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-2.0% Weak Weak Compound annual revenue growth over 5 years	11.5% Good Good Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	-336.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2344%)	—	—	-292.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2048%)	—	—
Effective Tax Rate (%) (%)	0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	5.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	24.3% Fair Fair Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	-296.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2567%)	—	—	-277.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2413%)	-404.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3474%)	—
FCF Margin (%) (%)	—	—	-304.3% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	—	-360.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-271.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.40x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-121.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-65.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	146.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-347.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-84.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-100.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-121.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-908%)	-58.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-493%)	-27.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-33.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-320%)	-17.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-215%)	146.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+876%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-1806.20x Weak Weak Operating income divided by interest expense Optimal: > 5x	-8576.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-12.36M	$-16.29M	$-51.16M	$-58.34M	$-240.42M	$-15.95M	$-41.07M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.12	$0.11	$0.47	$0.23	$0.30	—	—	—
Basic EPS, GAAP (USD)	$-1.59	$-1.65	$-1.38	$-1.64	$-2.11	—	—	—
Free Cash Flow per Share (USD)	$-1.20	$-1.58	$-1.42	$-1.60	$-1.09	—	—	—
Book Value per Share (USD)	$1.28	$2.74	$4.17	$4.93	$6.44	$-2.41	—	—
Tangible Book Value per Share (USD)	$1.28	$2.74	$4.17	$4.93	$6.44	$-2.41	—	—
Basic Weighted Avg Shares (shares)	93.39M	90.32M	73.81M	60.80M	31.66M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$119.82M	$188.73M	$310.54M	$232.12M	$365.36M	$11.92M	—	—
Total Equity (USD)	$122.17M	$252.95M	$368.40M	$300.87M	$387.82M	$-23.44M	$7.46M	$29.95M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$11.16M	$9.99M	$34.48M	$13.85M	$9.60M	$12.36M	$5.79M	—
Depreciation Expense (USD)	$3.65M	$3.93M	$3.52M	$1.62M	$984.00K	$900.00K	$751.00K	—
Net Income, GAAP (USD)	$-148.12M	$-149.10M	$-102.07M	$-99.42M	$-66.92M	$-34.31M	$-23.43M	—
Operating Cash Flow (USD)	$-110.99M	$-138.20M	$-93.29M	$-90.97M	$-32.52M	$-33.22M	$-32.01M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 28 quarters

Caribou Biosciences, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CRBU with peers